205 related articles for article (PubMed ID: 36923264)
1. Outcomes of SARS-CoV-2 infection in Ph-neg chronic myeloproliferative neoplasms: results from the EPICOVIDEHA registry.
Marchetti M; Salmanton-García J; El-Ashwah S; Verga L; Itri F; Ráčil Z; Dávila-Valls J; Martín-Pérez S; Van Doesum J; Passamonti F; Abu-Zeinah G; Farina F; López-García A; Dragonetti G; Cattaneo C; Gomes Da Silva M; Bilgin YM; Žák P; Petzer V; Glenthøj A; Espigado I; Buquicchio C; Bonuomo V; Prezioso L; Meers S; Duarte R; Bergantim R; Jaksic O; Čolović N; Blennow O; Cernan M; Schönlein M; Samarkos M; Mitra ME; Magliano G; Maertens J; Ledoux MP; Jiménez M; Demirkan F; Collins GP; Cabirta A; Gräfe SK; Nordlander A; Wolf D; Arellano E; Cordoba R; Hanakova M; Zambrotta GPM; Nunes Rodrigues R; Limberti G; Marchesi F; Cornely OA; Pagano L
Ther Adv Hematol; 2023; 14():20406207231154706. PubMed ID: 36923264
[TBL] [Abstract][Full Text] [Related]
2. Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant in Patients with Philadelphia-Negative Myeloproliferative Neoplasm: A Single Center Experience.
Ali EAH; Khamees I; Alshurafa A; Qasim H; Abu-Tineh MA; Ahmed K; Saad E; Yassin M
Oncology; 2022; 100(8):460-466. PubMed ID: 35882185
[TBL] [Abstract][Full Text] [Related]
3. Philadelphia-Negative Chronic Myeloproliferative Neoplasms during the COVID-19 Pandemic: Challenges and Future Scenarios.
Palandri F; Breccia M; De Stefano V; Passamonti F
Cancers (Basel); 2021 Sep; 13(19):. PubMed ID: 34638236
[TBL] [Abstract][Full Text] [Related]
4. Health care setting and severity, symptom burden, and complications in patients with Philadelphia-negative myeloproliferative neoplasms (MPN): a comparison between university hospitals, community hospitals, and office-based physicians.
Kaifie A; Isfort S; Gattermann N; Hollburg W; Klausmann M; Wolf D; Maintz C; Hänel M; Goekkurt E; Göthert JR; Platzbecker U; Geer T; Parmentier S; Jost E; Serve H; Ehninger G; Berdel WE; Brümmendorf TH; Koschmieder S;
Ann Hematol; 2016 Sep; 95(9):1399-410. PubMed ID: 27334946
[TBL] [Abstract][Full Text] [Related]
5. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
6. Risk Factors Associated With Mortality Among Patients With COVID-19 in Intensive Care Units in Lombardy, Italy.
Grasselli G; Greco M; Zanella A; Albano G; Antonelli M; Bellani G; Bonanomi E; Cabrini L; Carlesso E; Castelli G; Cattaneo S; Cereda D; Colombo S; Coluccello A; Crescini G; Forastieri Molinari A; Foti G; Fumagalli R; Iotti GA; Langer T; Latronico N; Lorini FL; Mojoli F; Natalini G; Pessina CM; Ranieri VM; Rech R; Scudeller L; Rosano A; Storti E; Thompson BT; Tirani M; Villani PG; Pesenti A; Cecconi M;
JAMA Intern Med; 2020 Oct; 180(10):1345-1355. PubMed ID: 32667669
[TBL] [Abstract][Full Text] [Related]
7. Outcomes following SARS-CoV-2 infection in liver transplant recipients: an international registry study.
Webb GJ; Marjot T; Cook JA; Aloman C; Armstrong MJ; Brenner EJ; Catana MA; Cargill T; Dhanasekaran R; García-Juárez I; Hagström H; Kennedy JM; Marshall A; Masson S; Mercer CJ; Perumalswami PV; Ruiz I; Thaker S; Ufere NN; Barnes E; Barritt AS; Moon AM
Lancet Gastroenterol Hepatol; 2020 Nov; 5(11):1008-1016. PubMed ID: 32866433
[TBL] [Abstract][Full Text] [Related]
8. Philadelphia-negative chronic myeloproliferative neoplasm follow-up: when the phone rings. Changes during the COVID-19 pandemic and patient satisfaction. Experience in 30 health centers in Spain.
Ortuzar A; Fox ML; Vera JA; Lorenzo Vizcaya Á; Marín Sánchez A; Llopis Calatayud I; Carbonell S; Álvarez-Larrán A; Mata Serna R; Marco Buades JE; Quiroz Cervantes K; Martínez Hellín Á; Blum Domínguez A; Caballero Navarro G; Cáceres Sansaloni A; Guerrero Fernández L; Muñoz Linares C; Gasior Kabat M; Pérez López R; Fernández Rodríguez Á; Martínez Bilbao C; Cobo Rodríguez MT; Díaz Á; Durán MA; Santaliestra Tomas M; García-Gutierrez V; Magro Mazo E; Hernández-Boluda JC; Segura A; Raya JM; Navas Elorza B; Osorio S
Ann Hematol; 2023 Feb; 102(2):447-456. PubMed ID: 36422672
[TBL] [Abstract][Full Text] [Related]
9. COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study.
Garassino MC; Whisenant JG; Huang LC; Trama A; Torri V; Agustoni F; Baena J; Banna G; Berardi R; Bettini AC; Bria E; Brighenti M; Cadranel J; De Toma A; Chini C; Cortellini A; Felip E; Finocchiaro G; Garrido P; Genova C; Giusti R; Gregorc V; Grossi F; Grosso F; Intagliata S; La Verde N; Liu SV; Mazieres J; Mercadante E; Michielin O; Minuti G; Moro-Sibilot D; Pasello G; Passaro A; Scotti V; Solli P; Stroppa E; Tiseo M; Viscardi G; Voltolini L; Wu YL; Zai S; Pancaldi V; Dingemans AM; Van Meerbeeck J; Barlesi F; Wakelee H; Peters S; Horn L;
Lancet Oncol; 2020 Jul; 21(7):914-922. PubMed ID: 32539942
[TBL] [Abstract][Full Text] [Related]
10. Role of Next Generation Immune Checkpoint Inhibitor (ICI) Therapy in Philadelphia Negative Classic Myeloproliferative Neoplasm (MPN): Review of the Literature.
Yadav R; Hakobyan N; Wang JC
Int J Mol Sci; 2023 Aug; 24(15):. PubMed ID: 37569880
[TBL] [Abstract][Full Text] [Related]
11. Myeloproliferative neoplasms treated with hydroxyurea, pegylated interferon alpha-2A or ruxolitinib: clinicohematologic responses, quality-of-life changes and safety in the real-world setting.
Gill H; Leung GMK; Yim R; Lee P; Pang HH; Ip HW; Leung RYY; Li J; Panagiotou G; Ma ESK; Kwong YL
Hematology; 2020 Dec; 25(1):247-257. PubMed ID: 32567517
[No Abstract] [Full Text] [Related]
12. High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib.
Barbui T; Vannucchi AM; Alvarez-Larran A; Iurlo A; Masciulli A; Carobbio A; Ghirardi A; Ferrari A; Rossi G; Elli E; Andrade-Campos MM; Kabat MG; Kiladjian JJ; Palandri F; Benevolo G; Garcia-Gutierrez V; Fox ML; Foncillas MA; Morcillo CM; Rumi E; Osorio S; Papadopoulos P; Bonifacio M; Cervantes KSQ; Serrano MS; Carreno-Tarragona G; Sobas MA; Lunghi F; Patriarca A; Elorza BN; Angona A; Mazo EM; Koschmieder S; Ruggeri M; Cuevas B; Hernandez-Boluda JC; Abadia EL; Cirici BX; Guglielmelli P; Garrote M; Cattaneo D; Daffini R; Cavalca F; Bellosillo B; Benajiba L; Curto-Garcia N; Bellini M; Betti S; De Stefano V; Harrison C; Rambaldi A
Leukemia; 2021 Feb; 35(2):485-493. PubMed ID: 33414483
[TBL] [Abstract][Full Text] [Related]
13. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
14. Severe Acute Respiratory Syndrome by SARS-CoV-2 Infection or Other Etiologic Agents Among Brazilian Indigenous Population: An Observational Study from the First Year of Coronavirus Disease (COVID)-19 Pandemic.
Sansone NMS; Boschiero MN; Ortega MM; Ribeiro IA; Peixoto AO; Mendes RT; Marson FAL
Lancet Reg Health Am; 2022 Apr; 8():100177. PubMed ID: 35018359
[TBL] [Abstract][Full Text] [Related]
15. The BCR-ABL1-negative myeloproliferative neoplasms: a review of JAK inhibitors in the therapeutic armamentarium.
Griesshammer M; Sadjadian P
Expert Opin Pharmacother; 2017 Dec; 18(18):1929-1938. PubMed ID: 29134817
[TBL] [Abstract][Full Text] [Related]
16. Determinants of COVID-19 disease severity in patients with underlying rheumatic disease.
Santos CS; Morales CM; Álvarez ED; Castro CÁ; Robles AL; Sandoval TP
Clin Rheumatol; 2020 Sep; 39(9):2789-2796. PubMed ID: 32720259
[TBL] [Abstract][Full Text] [Related]
17. Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study.
Barbui T; Ghirardi A; Masciulli A; Carobbio A; Palandri F; Vianelli N; De Stefano V; Betti S; Di Veroli A; Iurlo A; Cattaneo D; Delaini F; Bonifacio M; Scaffidi L; Patriarca A; Rumi E; Casetti IC; Stephenson C; Guglielmelli P; Elli EM; Palova M; Bertolotti L; Erez D; Gomez M; Wille K; Perez-Encinas M; Lunghi F; Angona A; Fox ML; Beggiato E; Benevolo G; Carli G; Cacciola R; McMullin MF; Tieghi A; Recasens V; Marchetti M; Griesshammer M; Alvarez-Larran A; Vannucchi AM; Finazzi G
Leukemia; 2019 Aug; 33(8):1996-2005. PubMed ID: 31142846
[TBL] [Abstract][Full Text] [Related]
18. Outcomes and Risk Factors Associated With SARS-CoV-2 Infection in a North American Registry of Patients With Multiple Sclerosis.
Salter A; Fox RJ; Newsome SD; Halper J; Li DKB; Kanellis P; Costello K; Bebo B; Rammohan K; Cutter GR; Cross AH
JAMA Neurol; 2021 Jun; 78(6):699-708. PubMed ID: 33739362
[TBL] [Abstract][Full Text] [Related]
19. Philadelphia-Negative Myeloproliferative Neoplasms Around the COVID-19 Pandemic.
Barbui T; De Stefano V
Curr Hematol Malig Rep; 2021 Oct; 16(5):455-463. PubMed ID: 34586561
[TBL] [Abstract][Full Text] [Related]
20. Investigational histone deacetylase inhibitors (HDACi) in myeloproliferative neoplasms.
Bose P; Verstovsek S
Expert Opin Investig Drugs; 2016 Dec; 25(12):1393-1403. PubMed ID: 27756180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
